Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Prolias Technologies
New York City, New York, United States
- Ownership
- Private
- Employees
- ~4
- Development stage
- Other
01
Overview
Prolias Technologies has two products ready for commercialization: THYMIRA™ Panel for differentiating malignant from benign thyroid nodules, and ARMIRA™ Panel for non-invasive kidney rejection diagnosis
- Therapeutic areas
- EndocrinologyNephrology
- Modalities
- Molecular diagnostic test (microRNA-based)
- Industry
- Molecular Diagnostics
02
Partnerships
Cornell University (licensed microRNA diagnostic portfolio from Weill Cornell Medical College)
Beyond the preview
Go deeper on Prolias Technologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prolias Technologies.